Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Receivables: 2014-2021

Historic Receivables for Agios Pharmaceuticals (AGIO) over the last 6 years, with Dec 2021 value amounting to $4.4 million.

  • Agios Pharmaceuticals' Receivables was N/A to $4.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $54.7 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2021, which is N/A change from last year.
  • According to the latest figures from Q4 2021, Agios Pharmaceuticals' Receivables is $4.4 million, which was down 79.47% from $21.3 million recorded in Q3 2020.
  • In the past 5 years, Agios Pharmaceuticals' Receivables ranged from a high of $38.7 million in Q2 2018 and a low of $2.4 million during Q4 2017.
  • Moreover, its 3-year median value for Receivables was $10.1 million (2019), whereas its average is $11.3 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Receivables skyrocketed by 587.64% in 2018 and then slumped by 74.98% in 2019.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Receivables stood at $2.4 million in 2017, then spiked by 207.92% to $7.5 million in 2018, then skyrocketed by 39.17% to $10.5 million in 2019, then surged by 138.41% to $21.3 million in 2020, then reached $4.4 million in 2021.
  • Its last three reported values are $4.4 million in Q4 2021, $21.3 million for Q3 2020, and $14.6 million during Q2 2020.